DE60330857D1 - 5-ht4 antagonisten zur behandlung von herzversagen - Google Patents

5-ht4 antagonisten zur behandlung von herzversagen

Info

Publication number
DE60330857D1
DE60330857D1 DE60330857T DE60330857T DE60330857D1 DE 60330857 D1 DE60330857 D1 DE 60330857D1 DE 60330857 T DE60330857 T DE 60330857T DE 60330857 T DE60330857 T DE 60330857T DE 60330857 D1 DE60330857 D1 DE 60330857D1
Authority
DE
Germany
Prior art keywords
heart failure
antagonists
heart
treatment
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60330857T
Other languages
English (en)
Inventor
Finn Olav Levy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serodus AS
Original Assignee
Serodus AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serodus AS filed Critical Serodus AS
Application granted granted Critical
Publication of DE60330857D1 publication Critical patent/DE60330857D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Treatment Of Sludge (AREA)
DE60330857T 2002-05-16 2003-05-16 5-ht4 antagonisten zur behandlung von herzversagen Expired - Lifetime DE60330857D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0211230.8A GB0211230D0 (en) 2002-05-16 2002-05-16 Treatment of heart failure
PCT/GB2003/002134 WO2003097065A1 (en) 2002-05-16 2003-05-16 5-ht4 receptor antagonists for the treatment of heart failure

Publications (1)

Publication Number Publication Date
DE60330857D1 true DE60330857D1 (de) 2010-02-25

Family

ID=9936797

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60330857T Expired - Lifetime DE60330857D1 (de) 2002-05-16 2003-05-16 5-ht4 antagonisten zur behandlung von herzversagen

Country Status (11)

Country Link
US (2) US20060094715A1 (de)
EP (1) EP1503764B1 (de)
AT (1) ATE454153T1 (de)
AU (2) AU2003227949B2 (de)
CA (1) CA2485600C (de)
DE (1) DE60330857D1 (de)
DK (1) DK1503764T3 (de)
ES (1) ES2339234T3 (de)
GB (1) GB0211230D0 (de)
HK (1) HK1072012A1 (de)
WO (1) WO2003097065A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9890119B2 (en) 2013-02-27 2018-02-13 Shionogi & Co., Ltd. Indole and azaindole derivative having AMPK-activating activity
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
EP3113777A4 (de) * 2014-03-04 2017-09-06 The Children's Hospital of Philadelphia Verfahren zum management der behandlung von patienten mit prädisposition für progressive mitralklappenerkrankungen
CA3020815A1 (en) * 2016-04-13 2017-10-19 Board Of Regents Of The University Of Nebraska Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
CA3151788A1 (en) * 2019-09-20 2021-03-25 Jingchao Sun Uses of complex of angiotensin ii receptor antagonist metabolite and nep inhibitor in treating heart failure

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0018002B1 (de) 1979-04-24 1983-02-09 Marcel Jozefonvicz Neues Bestimmungsverfahren für Proteasen und Antiproteasen
US4888353A (en) 1986-02-28 1989-12-19 Erbamont, Inc. Carboxamides useful as antiemetic or antipsychotic agents
DE385517T1 (de) 1985-03-14 1991-07-25 Beecham Group p.l.c., Brentford, Middlesex Arzneimittel zur behandlung von erbrechen.
US4851423A (en) 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
IL87674A (en) 1987-09-08 1993-08-18 Lilly Co Eli Azabicycloalkyl esters and amides of heterocyclic acids, their preparation and pharmaceutical compositions containing them
CA1317940C (en) 1987-09-25 1993-05-18 Georges H. P. Van Daele Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
ZA889493B (en) 1987-12-24 1989-09-27 Duphar Int Res Method of preparing optically active cyanohydrin derivatives and their conversion products,and optically active compounds to be obtained in this manner
US4859683A (en) * 1988-02-04 1989-08-22 Rorer Pharmaceutical Corporation Certain benzoxepins and their pharmaceutical compositions and methods
JP2643274B2 (ja) 1988-04-08 1997-08-20 三菱化学株式会社 イミダゾ〔１，２−ａ〕ピリジン誘導体
EP0387431A1 (de) 1989-03-14 1990-09-19 Beecham Group Plc Imidazolderivate, Verfahren zu deren Herstellung und deren Anwendung als pharmazeutische Mittel
KR920701167A (ko) 1989-07-07 1992-08-11 에릭 에스. 딕커 약제학적 활성 화합물
GB9009389D0 (en) * 1990-04-26 1990-06-20 Smith Kline French Lab Treatment
GB9103862D0 (en) 1991-02-25 1991-04-10 Glaxo Group Ltd Chemical compounds
US5196547A (en) * 1991-03-07 1993-03-23 G. D. Searle & Co. Meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5219850A (en) * 1991-03-07 1993-06-15 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5260303A (en) * 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
US5137893A (en) * 1991-03-07 1992-08-11 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
WO1993002677A1 (en) 1991-08-03 1993-02-18 Smithkline Beecham Plc 5-ht4 receptor antagonists
AU2435092A (en) 1991-08-20 1993-03-16 Smithkline Beecham Plc 5-ht4 receptor antagonists
EP0603220A1 (de) 1991-09-12 1994-06-29 Smithkline Beecham Plc Azabicyclische Verbindungen als 5-HT4 Rezeptor Antagonisten
ATE182591T1 (de) 1991-09-12 1999-08-15 Smithkline Beecham Plc 5-ht4 rezeptor antagonisten
GB9121835D0 (en) 1991-10-15 1991-11-27 Smithkline Beecham Plc Pharmaceuticals
US20020128172A1 (en) * 1991-12-21 2002-09-12 Smithkline Beecham Plc Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
US5708174A (en) 1992-03-12 1998-01-13 Smithkline Beecham P.L.C. Heterocyclic-esters or -amides used as 5-HT4 receptor antagonists
EP0884319B1 (de) 1992-03-12 2004-05-06 SmithKline Beecham plc N- (1-nButyl-4-piperidyl)methyl -3,4-dihydro-2H- 1,3 oxazino 3,2-a indol-10-carboxamid oder ein pharmazeutisch annehmbares Salz davon
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
GB9219163D0 (en) 1992-09-10 1992-10-28 Smithkline Beecham Plc Pharmaceuticals
MX9305947A (es) 1992-09-29 1994-06-30 Smithkline Beecham Plc Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
MX9306311A (es) 1992-10-13 1994-04-29 Smithkline Beecham Plc Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
GB9221468D0 (en) 1992-10-13 1992-11-25 Smithkline Beecham Plc Pharmaceuticals
EP0664794A1 (de) 1992-10-16 1995-08-02 Smithkline Beecham Plc N-alkylpiperidinyl-4-methyl-carbonsäure ester/amide von kondensierten ring-systemen als 5-ht4-rezeptor antagonisten
NZ257545A (en) 1992-11-05 1997-01-29 Smithkline Beecham Plc Heterocyclic (especially piperidine) derivatives and pharmaceutical compositions
US5472866A (en) * 1992-12-24 1995-12-05 Synaptic Pharmaceutical Corporation DNA encoding 5-HT4A serotonin receptors
GB9301660D0 (en) 1993-01-28 1993-03-17 Smithkline Beecham Plc Pharmaceuticals
US6127379A (en) * 1993-02-01 2000-10-03 Smithkline Beecham P.L.C. Benzopyran, benzothiopyran and benzofuran derivatives as 5-HT4 antagonists
GB9310582D0 (en) * 1993-05-22 1993-07-07 Smithkline Beecham Plc Pharmaceuticals
TW282460B (de) 1993-12-28 1996-08-01 Yamanouchi Pharma Co Ltd
EP0774460A1 (de) 1994-03-30 1997-05-21 Yoshitomi Pharmaceutical Industries, Ltd. Benzosäurederivate und ihre medizinische verwendung
JPH07302236A (ja) * 1994-05-06 1995-11-14 Hitachi Ltd 情報処理システムおよびその方法並びに情報処理システムにおけるサービス提供方法
AU6856094A (en) 1994-06-01 1995-12-21 Yamanouchi Pharmaceutical Co., Ltd. Oxadiazole derivative and medicinal composition thereof
WO1996005166A1 (fr) 1994-08-11 1996-02-22 Yamanouchi Pharmaceutical Co., Ltd. Derive d'amine substitue et composition medicamenteuse le contenant
GB2311071B (en) * 1994-11-21 1998-12-23 Asahi Chemical Ind Curable resin and resin composition comprising the same
ES2103675B1 (es) 1995-01-10 1998-07-01 Almirall Lab Nuevas piperidinas sustituidas.
IT1275903B1 (it) * 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
JPH0967347A (ja) 1995-08-30 1997-03-11 Dainippon Pharmaceut Co Ltd 環状アミン誘導体及びそれを含有する医薬組成物
CZ287268B6 (en) * 1995-11-09 2000-10-11 Sanofi Synthelabo Derivatives of 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one, process of their preparation and pharmaceutical preparation in which they are comprised
WO1997027852A1 (en) 1996-01-30 1997-08-07 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DE69725345T2 (de) * 1996-02-15 2004-08-19 Janssen Pharmaceutica N.V. Verwendung von 5-ht4 antagonisten zur überwindung der gastrointestinalen beschädigung, die durch inhibitoren der serotonin-wiederaufnahme hervorgerufen werden
CA2249601A1 (en) 1996-04-03 1997-10-23 Thorsten E. Fisher Inhibitors of farnesyl-protein transferase
CN1104435C (zh) 1996-08-16 2003-04-02 史密丝克莱恩比彻姆有限公司 N－[(1－正丁基－4－哌啶基)甲基]－3,4－二氢－2H－[1,3] 噁嗪并[3,2－α]吲哚－10－甲酰胺及其盐的制备方法及在本方法中的中间体的制备方法
FR2752736B1 (fr) 1996-08-30 1998-10-23 Chu Rouen Utilisation d'antagonistes 5-ht4 dans la regulation de la secretion de corticosteroides
GB9618967D0 (en) 1996-09-11 1996-10-23 Smithkline Beecham Plc Pharmaceuticals
JPH10203987A (ja) 1997-01-28 1998-08-04 Dainippon Pharmaceut Co Ltd （ｒ）−１−エチル−４−メチルヘキサヒドロ−１ｈ−１，４−ジアゼピン誘導体を有効成分とするモルヒネ様薬剤誘発嘔吐抑制剤
FR2762316B1 (fr) * 1997-04-18 1999-12-17 Sanofi Synthelabo Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
EP1068185A1 (de) 1998-03-31 2001-01-17 Acadia Pharmaceuticals Inc. Verbindungen mit wirkung auf muskarin-rezeptoren
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
GB9815483D0 (en) 1998-07-16 1998-09-16 Smithkline Beecham Plc Pharmaceuticals
GB9815481D0 (en) 1998-07-16 1998-09-16 Smithkline Beecham Plc Pharmaceuticals
US20020091271A1 (en) * 1998-07-16 2002-07-11 Smithkline Beecham Plc Process for the preparation of an indole derivative
JP4032566B2 (ja) 1999-06-21 2008-01-16 東レ株式会社 発光素子
EP1216971A1 (de) * 1999-08-27 2002-06-26 Qingdao Synergy Technology Appliance Co., Ltd. Verfahren zur herstellung von isolierverglasung und mechanisches system zur anwendung
EP1311295A2 (de) * 2000-08-07 2003-05-21 Laboratoire Glaxosmithkline S.A.S. Verwendung von 5ht4 rezeptor antagonisten zur herstellung eines medikaments für die vorbeugung oder behandlung von vorhof-fibrillation
WO2002011733A1 (en) 2000-08-08 2002-02-14 Smithkline Beecham P.L.C. Pharmaceutical composition comprising condensed indole compound
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
JP2005526003A (ja) * 2001-10-22 2005-09-02 ファイザー株式会社 ５−ｈｔ４受容体調節剤としてのイミダゾピリジン化合物
US6624162B2 (en) * 2001-10-22 2003-09-23 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor modulators
MXPA03000145A (es) * 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
DK1476136T3 (da) 2002-02-14 2006-10-09 Glaxo Group Ltd Farmaceutisk præparat, der omfatter N-[(1-N-butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indol-10-carboxamid eller salt, og fremgangsmåde derfor, der omfatter törgranulering
DOP2003000703A (es) 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
WO2004104577A2 (en) 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
PL1664036T3 (pl) 2003-09-03 2012-04-30 Pfizer Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4
US7834010B2 (en) 2003-12-23 2010-11-16 Serodus As Modulators of peripheral 5-HT receptors
MXPA06007853A (es) 2004-01-07 2007-01-26 Aryx Therapeutics Compuestos estereoisomericos y metodos para el tratamiento de desordenes gastrointestinales y del sistema nervioso central.
WO2006038351A1 (ja) * 2004-09-30 2006-04-13 Sharp Kabushiki Kaisha 結晶質半導体膜およびその製造方法
WO2007007072A1 (en) 2005-07-07 2007-01-18 Bio-Medisinsk Innovasjon As 5-htx modulators
ES2333545T3 (es) 2005-07-22 2010-02-23 Pfizer, Inc. Derivados de indazolcarboxamida como agonistas de receptores 5ht4.
WO2007149929A1 (en) 2006-06-23 2007-12-27 Aryx Therapeutics, Inc. Piperidine derivatives for the treatment of gastrointestinal and cns disorders
JO2653B1 (en) 2006-10-24 2012-06-17 شركة جانسين فارماسوتيكا ان. في Tetrahydroflavin 1-carboxylic acid substituted with pyridine or pyrazine inhibit MTB

Also Published As

Publication number Publication date
DK1503764T3 (da) 2010-05-10
GB0211230D0 (en) 2002-06-26
EP1503764A1 (de) 2005-02-09
AU2003227949B2 (en) 2008-12-11
WO2003097065A1 (en) 2003-11-27
ATE454153T1 (de) 2010-01-15
EP1503764B1 (de) 2010-01-06
US20060094715A1 (en) 2006-05-04
US20090169545A1 (en) 2009-07-02
ES2339234T3 (es) 2010-05-18
US8829028B2 (en) 2014-09-09
CA2485600C (en) 2010-04-20
HK1072012A1 (en) 2005-08-12
CA2485600A1 (en) 2003-11-27
AU2003227949A1 (en) 2003-12-02
AU2009200050A1 (en) 2009-02-05
AU2009200050B2 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
WO2005107726A3 (en) Method for the treatment of back pain
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
TNSN07376A1 (en) Npy antagonists, preparation and use
MX2007002311A (es) Antagonistas del receptor de endotelina a(eta) en combinacion con inhibidores de fosfodiesterasa 5 (pdes) y usos de los mismos.
WO2006015775A3 (en) Egfr kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
TW200633980A (en) Pyridones useful as inhibitors of kinases
HK1096673A1 (en) Compositions useful as inhibitors of protein kinases
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
WO2005014533A3 (en) Aryl and heteroaryl compounds, compositions, and methods of use
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
MXPA04001187A (es) Receptores de interleucina-1 en el tratamiento de enfermedades.
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
NO20052272L (no) CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
ATE465735T1 (de) Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen
HK1072012A1 (en) 5-ht4 receptor antagonists for the treatment of heart failure
ATE509957T1 (de) An die a2-domäne bindende, humane inhibitorische anti-faktor-viii-antikörper

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: KUDLEK & GRUNERT PATENTANWAELTE PARTNERSCHAFT, 803

8364 No opposition during term of opposition